康奈尔大学博士后职位招聘–计算生物学家
The Cancer and Glioma Stem Cell Biology Laboratory, part of the Weill Cornell Brain Tumor Center and Meyer Cancer Center, is a highly interactive, translational research laboratory dedicated to the discovery of new basic cancer biology and the translational of those discoveries into novel experimental therapeutics destined for the clinic. The laboratory (a 2017 recipient of the NIH Directors Pioneer Award) is a highly translational program/laboratory benefitting from exceptional resources, scientific freedom and extraordinary local environment of world-renowned cancer biologists and neuroscientists. Our largest and most rapidly growing area of interest focuses on single cell genomic and epigenomic gene regulatory networks and the resultant developmental biology of the human brain and malignant glioma stem cells as influenced by the central nervous system’s host microenvironment using a number of novel patient-derived ex vivo tumor models including studies in embryonic and induced pluripotent stem cell-derived cerebral organoids. Our high throughput drug screening core then allows the genetic and drug screening of promising network targets for dissecting out new biology and developing promising new therapeutics.
A few of our publications that represent the kind of research we do include: Cancer Cell 39:1056, 2021; Cancer Discovery 10:964-979, 2020; Cancer Discovery 9:1650-52, 2019; Cell Reports 26:3201-11, 2019; Cancer Cell. 9: 287-300, 2006; Cancer Research. 66(19): 9428-36, 2006; Cancer Cell. 9(5):391-403, 2006; Cancer Res. 6(1):21-30, 2008; Cancer Cell 13(1):69-80, 2008; Cell Stem Cell. 4(5): 440-52, 2009.; Cancer Research, 2009; 69(4): 1596-1603, 2009; Cancer Cell.15(4): 247-9, 2009; Cell Stem Cell 4(6): 466-7, 2009; Bioinformatics. 26:1792-3, 2010; Cancer Cell. 18:543-5, 2010; Nature Reviews Neurol 7:439-50, 2011; PLoS One 6:e14681, 2011, Cancer Cell 20:695-7, 2011; J. Natl. Cancer Instit. 103:1162-78, 2011; Cancer Cell 21; 710, 2012; PLOS One 7:e51407, 2012, Cell Reports 6:313, 2014; PLoS One. 2014 Nov 3;9(11):e111783. doi: 10.1371; Cancer Inform. 2014 Oct 15;13(Suppl 3):33-44. doi: 10.4137; Pharmacogenomics J. 2014 Dec 2. doi: 10.1038/tpj.2014.61.
The laboratory allows outstanding exposure to and potential involvement in all aspects of translational science while exploring basic mechanistic studies of tumorigenesis using a combination of molecular and computational biology approaches.
The position is a purely academic research one with the major responsibilities being to provide computational expertise in the analyses of large genetic and epigenetic “-omics” data, most importantly single cell RNA-seq, ATAC-seq and DNA sequence analyses. It is expected that the successful candidate will, in collaboration with colleagues in the laboratory and the laboratory principle investigator, Dr. Fine, write scholarly manuscripts and publish biomedical research papers in high impact peer reviewed journals.
Please email a letter of interest and curriculum vitae to Howard A. Fine, M.D. at: haf9016@med.cornell.edu.
